Catalent Said to Seek $400 Million Loan for Aptuit Unit Purchase
Feb. 13 (Bloomberg) -- Catalent Pharma Solutions Inc., the provider of development services to the pharmaceutical industry, is seeking a $400 million term loan to back its acquisition of Aptuit LLC’s clinical trial supplies business, according to a person with knowledge of the transaction.
Morgan Stanley is arranging the financing for the Somerset, New Jersey-based company and will hold a lender call at 10:30 a.m. tomorrow in New York, said the person, who asked not to be identified because details haven’t been publicized.
2643734Z US <equity> CN
To contact the editor responsible for this story: Dennis Fitzgerald at email@example.com